5533-01-7

Usage

General Description

Benzenemethanol, 3-methoxy-4-(methoxymethoxy)- is a chemical compound that is derived from benzyl alcohol and contains an ether functional group. It has the molecular formula C10H14O3 and is commonly used as a solvent and intermediate in the synthesis of pharmaceuticals and fragrances. Benzenemethanol, 3-methoxy-4-(methoxymethoxy)- has a wide range of applications in industries such as cosmetics, food, and pharmaceuticals due to its solubility and stability properties. It is important to handle this chemical with care and follow proper safety protocols due to its potential hazards and toxicity.

Upstream product

• 121-33-5 vanillin 
• 13057-17-5 bromethyl methyl ether 
• 5533-00-6 3-methoxy-4-methoxymethoxy-benzaldehyde 

Downstream Products

• 491853-67-9 3-methoxy-4-(methoxymethoxy)benzyl iodide 
• 926889-00-1 acetic acid 3-methoxy-4-methoxymethoxy-benzyl ester 
• 926889-04-5 1-azidomethyl-2-chloro-5-methoxy-4-methoxymethoxy-benzene 
• 926889-05-6 1-azidomethyl-2-bromo-5-methoxy-4-methoxymethoxy-benzene 
• 926889-06-7 1-azidomethyl-2-iodo-5-methoxy-4-methoxymethoxy-benzene 
• 926889-08-9 1-bromo-2-isothiocyanatomethyl-4-methoxy-5-methoxymethoxy-benzene 
• 926889-07-8 1-chloro-2-isothiocyanatomethyl-4-methoxy-5-methoxymethoxy-benzene 
• 926889-01-2 acetic acid 2-chloro-5-methoxy-4-methoxymethoxy-benzyl ester 
• 926889-02-3 acetic acid 2-bromo-5-methoxy-4-methoxymethoxy-benzyl ester 
• 926889-09-0 1-iodo-2-isothiocyanatomethyl-4-methoxy-5-methoxymethoxy-benzene 
• 926889-03-4 acetic acid 2-iodo-5-methoxy-4-methoxymethoxy-benzyl ester 
• 928673-70-5 1-(2-bromo-5-methoxy-4-methoxymethoxy-benzyl)-3-(4-tert-butyl-benzyl)-thiourea 
• 928673-69-2 1-(4-tert-butyl-benzyl)-3-(2-chloro-5-methoxy-4-methoxymethoxy-benzyl)-thiourea 
• 928673-71-6 1-(4-tert-butyl-benzyl)-3-(2-iodo-5-methoxy-4-methoxymethoxy-benzyl)-thiourea 

Relevant academic research and scientific papers

Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design

The inhibition of glutaminyl cyclase (QC) may provide a promising strategy for the treatment of early Alzheimer's disease (AD) by reducing the amount of the toxic pyroform of β-amyloid (AβΝ3pE) in the brains of AD patients. In this work, we ide

Drug compound for treating hepatopathy and application thereof

The invention discloses a drug compound for treating hepatopathy and application thereof. The drug compound specifically serves as a compound shown in general formula (I) or an optical isomer or a pharmaceutically-acceptable salt of the compound. The compound or the optical isomer or the pharmaceutically-acceptable salt of the compound has a good curative effect and low toxicity on hepatopathy, especially fatty liver. Experiments show that the compound has an obvious protective effect on zebrafish nonalcoholic fatty liver, so that the drug compound has a good application prospect in medicinesfor treatment or prevention of hepatopathy, especially fatty liver or liver fibrosis or liver cirrhosis.

Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands

The chiral isomers of the two potent simplified RTX-based vanilloids, compounds 2 and 3, were synthesized employing highly enantioselective PTC alkylation and evaluated as hTRPV1 ligands. The analysis indicated that the R-isomer was the eutomer in binding affinity and functional activity. The agonism of compound 2R was comparable to that of RTX. Docking analysis of the chiral isomers of 3 suggested the basis for its stereospecific activity and the binding mode of 3R.

Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands

The chiral isomers of the two potent simplified RTX-based vanilloids, compounds 2 and 3, were synthesized employing highly enantioselective PTC alkylation and evaluated as hTRPV1 ligands. The analysis indicated that the R-isomer was the eutomer in binding affinity and functional activity. The agonism of compound 2R was comparable to that of RTX. Docking analysis of the chiral isomers of 3 suggested the basis for its stereospecific activity and the binding mode of 3R.

Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands

The chiral isomers of the two potent simplified RTX-based vanilloids, compounds 2 and 3, were synthesized employing highly enantioselective PTC alkylation and evaluated as hTRPV1 ligands. The analysis indicated that the R-isomer was the eutomer in binding affinity and functional activity. The agonism of compound 2R was comparable to that of RTX. Docking analysis of the chiral isomers of 3 suggested the basis for its stereospecific activity and the binding mode of 3R.

Halogenation of 4-hydroxy-3-methoxybenzyl thiourea TRPV1 agonists showed enhanced antagonism to capsaicin

Selected potent TRPV1 agonists (1-6) have been modified by 5- or 6-halogenation on the aromatic A-region to analyze their effects on potency and efficacy (agonism versus antagonism). The halogenation caused enhanced functional antagonism at TRPV1 compared to the corresponding prototype agonists. The analysis of SAR indicated that the antagonism was enhanced as the size of the halogen increased (I > Br > Cl) and when the 6-position was halogenated. Compounds 23c and 31b were found to be potent full antagonists with Ki (as functional antagonist) = 23.1 and 30.3 nM in rTRPV1/CHO system, respectively.

Synthesis of deuterium labeled silybin and isosilybin

A simple synthesis of the deuterium labeled (+)-silybin [(+)-1c,d], (+)-isosilybin [(+)-2c,d] and their 1,4-benzodioxane building block [rac.-1f] have been achieved in seven steps starting from vanilline (5).

Synthesis and 11c-labelling of (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4 ′-hydroxystyryl) benzene for PET imaging of amyloid deposits

Carboxylic acid derivatives of the amyloid-binding dye Congo red do not enter the brain well and are thus unable to serve as in vivo amyloid-imaging agents. A neutral amyloid probe, (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4 ′-hydroxystyryl)benzene (3), devoid of any carboxylate groups has been designed and synthesized via a 12-step reaction sequence with a total yield of 30%. The unsymmetric compound 3 has also been labelled with C-11 via [11C]methyl iodide ([11C]CH3I) methylation of a symmetric 4,4′-dimesyl protected precursor followed by deprotection. Preliminary evaluation indicated that compound 3 selectively stained plaques and neurofibrillary tangles in post-mortem AD brain, and exhibited good binding affinity (Ki = 38 ± 8 nM) for Aβ(1-40) fibrils in vitro. In vivo pharmacokinetic studies indicated that [11C]3 exhibited higher brain uptake than its carboxylic acid analogs and good clearance from normal control mouse brain. [11C]3 also exhibited specific in vivo binding to pancreatic amyloid deposits in the NOR-beta transgenic mouse model. These results justify further investigation of 3 and similar derivatives as surrogate markers for in vivo quantitation of amyloid deposits. Copyright